Selected Important Safety Information
Continuous intravenous (IV) infusions of Remodulin are delivered using a tube placed in a central vein within the chest.
This type of delivery is associated with the risk of blood stream infections and sepsis, which may be fatal. Therefore,
continuous subcutaneous (SC) infusion delivered just beneath the skin is the preferred type of delivery.
You should not stop or greatly reduce your Remodulin dose without consulting your doctor, as this may cause your PAH symptoms to worsen.
*Based on data collected from US prescribers by Guidepoint Global, LLC, for subscription data as of March 2015. br>
†When prepared using a sterile high-pH glycine diluent. Remodulin cannot be stored for 14 days when mixed with
Sterile Water for Injection or Sodium Chloride Injection. The CADD-MS® 3
should not be used for premixing. Stability was demonstrated as low as 0.004 mg/mL.
Remodulin is a prescription medication used in adults with pulmonary arterial hypertension (PAH; WHO Group 1),
to diminish symptoms associated with exercise. PAH is high blood pressure in the arteries of your lungs. Remodulin
was studied mainly in patients with NYHA Functional Class II-IV symptoms. Remodulin is delivered (infused) continuously
using a pump connected to a small tube that is either placed under the skin (subcutaneously [SC]) or inserted into a
vein in the upper chest (intravenously [IV]). Because there are risks associated with continuous IV infusion, such as
serious blood stream infections, IV infusion should be reserved for people who cannot tolerate SC infusion or for those
in whom the risks are considered acceptable.
In people with PAH who need to switch from Flolan® (epoprostenol sodium), Remodulin is approved to slow the worsening of
symptoms. The risks and benefits of each drug should be carefully considered before switching.
Important Safety Information
- Continuous intravenous (IV) infusions of Remodulin are delivered using a tube placed in a central vein within the chest. This type of delivery is associated with the risk of blood stream infections and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion delivered just beneath the skin is the preferred type of delivery.
- You should not stop or greatly reduce your Remodulin dose without consulting your doctor, as this may cause your PAH symptoms to worsen.
- Other medical conditions and medicines may affect your use of Remodulin by increasing the risk of side effects or decreasing the drug's effectiveness. It is important to tell your doctor about your medical conditions and any medicines you may be taking.
- If you have liver or kidney problems, your ability to tolerate Remodulin may be affected.
- If you are taking gemfibrozil (for high cholesterol), rifampin (for infection), or other drugs that affect liver enzymes, your doctor may need to adjust your Remodulin dosage.
- Remodulin acts by lowering your blood pressure. In some cases your blood pressure may become too low and cause other side effects. If you also take other drugs that lower your blood pressure, the risk is increased. You should discuss all of your symptoms with your doctor, including those associated with low blood pressure.
- Because Remodulin can reduce the blood's ability to clot, it may increase your risk of bleeding, especially if you are taking anticoagulants (blood thinners).
- If you are pregnant, breast-feeding, or planning to become pregnant, talk with your doctor about whether you should take Remodulin.
- Side Effects: In clinical studies of SC infusion of Remodulin, most people experienced infusion site pain and infusion site reaction (redness and swelling). These symptoms were often severe and sometimes required treatment with narcotics or discontinuation of Remodulin. The IV infusion of Remodulin has been associated with the risk of blood stream infections, arm swelling, tingling sensations, bruising, and pain. Other common side effects seen with either SC or IV Remodulin were headache, diarrhea, jaw pain, nausea, vasodilatation (widening of the blood vessels), and edema (swelling).
For more information about REMODULIN, please see the Full Prescribing Information.
Questions? Call the Customer Service Line at 1-877-UNITHER (1-877-864-8437).